Eris Lifesciences will purchase the final 30% stake in Swiss Parenterals through a Rs 423-crore share swap, aiming for full consolidation, greater cost efficiency and strengthened strategic control
Read Full
Your email address will not be published. Required fields are marked *
Save my name, email, and website in this browser for the next time I comment.
